liraglutide versus semaglutide Frontiers Liraglutide exposure and body weight

PF-05221304 (PF1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and alt - phase 2a, dose-ranging study [abstract]

The new triple agonists coming out in 2026 may even offer more benefits but we do need more long term research on this

Q6. Can ALCAR help with physical performance as well

In parallel, increasing attention has focused on the gut microbiota as a regulator of host metabolism and enteroendocrine signaling

They also point out that they cannot show a correlation between the dose of semaglutide prescribed and the incidence of NAION or that stopping semaglutide was associated with an improvement in NAION, both of which would be needed to suggest causation

Narcolepsy evidence is inadequate